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Bestatin, a small molecular weight dipeptide, is a potent inhibitor of various aminopeptidases 
as well as LTA4 hydrolase. Various physiological functions of Bestatin have been identified, 
viz.: (1) an immunomodifier for enhancing the proliferation of normal human bone marrow 
granulocyte–macrophage progenitor cells to form CFU-GM colonies; Bestatin exerts a direct 
stimulating effect on lymphocytes via its fixation on the cell surface and an indirect effect on 
monocytes via aminopeptidase B inhibition of tuftsin catabolism; (2) an immunorestorator and 
curative or preventive agent for spontaneous tumor; Bestatin alone or its combination with 
chemicals can prolongate the disease-free interval and survival period in adult acute or chronic 
leukemia, therefore, it was primarily marketed in 1987 in Japan as an anticancer drug and 
servers as the only marketed inhibitor of Aminopeptidase N (APN/CD13) to cure leukemia to 
date; (3) a pan-hematopoietic stimulator and restorator; Bestatin promotes granulocytopoiesis 
and thrombocytopoiesis in vitro and restores them in myelo-hypoplastic men; (4) an inhibitor of 
several natural opioid peptides. Based on the knowledge that APN can cleave several bioactive 
neuropeptides such as Met-enkaphalins, Leu-enkaphalins, β-Endorphin, and so on, the anti-
aminopeptidase action of Bestatin also allows it to protect endopeptides against their catabolism, 
exhibiting analgesic activity. Although many scientific studies and great accomplishments have 
been achieved in this field, a large amount of problems are unsolved. This article reviews the 
promising results obtained for future development of the analgesic activity of Bestatin that can 
be of vital interest in a number of severe and chronic pain syndromes.
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Enkaphalin has a higher affinity for the δ receptor (Chaillet et al., 
1984), whereas the Dyn more readily acts as the ligand of the κ 
subtype (Han and Xie, 1982).
Despite their marked functions, the majority of opioid peptides 
undergo rapid enzymatic degradation (Egleton et al., 1998). Most of 
the extracellular peptide-degrading enzymes are membrane-bound 
exo- and endopeptidases and aminopeptidase N is one of these 
crucial enzymes. APN is a transmembrane protease present in a 
wide range of human tissues and cell types (endothelial, epithelial, 
fibroblast, leukocyte), which is able to modulate bioactive peptide 
responses and to influence immune functions. APN is responsi-
ble for the degradation of several biologically active peptide sub-
strates including Enkaphalins, neurokinin A and β-EP (Miller et al., 
1994; Lucius et al., 1995; Bauvois and Dauzonne, 2006; Luan and 
Xu, 2007), which, therefore, can be considered as a useful clinical 
marker. It can be expected that opiate peptides-operated neural 
activity is potentiated by peptidase inhibitors.
Bestatin, N-(2S, 3R)-3-amino-2-hydroxy-4-phenyl butanoyl) 
l-leucine  (Figure 1),  was  extracted  from  Streptomyces  olivore-
ticuli (Umezawa et al., 1976) and totally synthesized by Suda et al. 
(1976) for the first time adopting the following synthetic routine 
(Figure 2). As a potent APN inhibitor, its wide application in the 
immune system has been searched for a long history, affirming 
its  functions  in  immunomodification  (Umezawa  et  al.,  1976; 
Mathe, 1991), immunorecovery (Bruley-Rosset et al., 1979; Ota 
and Ogawa, 1990), hematopoiesis (Talmadge et al., 1990), anti-
nociception (Mathe, 1991; Miller et al., 1994). Among these, its 
IntroductIon
The  endogenous  opioids  comprising  Met-Enkaphalins  (ME), 
Leu-Enkaphalins (LE), β-Endorphin (β-EP), Dynorphin (Dyn), 
Kyotorphin (KTP), Endomorphin, (EM) and numerous others all 
belong to the family of pain-killing opioid peptides, which potently 
agitate opioid receptors to attain the antinociceptive effect (Frenk 
et al., 1978; Schwartz et al., 1981; Lee et al., 2004). The relevant 
opioid receptors belong to the family of G-protein coupled recep-
tors with at least four subtypes [κ-opioid receptor (KOR), μ-opioid 
receptor (MOR), δ-opioid receptor (DOR), and σ-opioid receptor] 
being found in the human central nervous system contributing to 
the analgesia. These endogenous opioids, which work as “natural 
pain relievers” by decreasing the perception of pain, have a homog-
enous structural relationship as they usually possess tyrosine as 
an N-terminal amino acid residue, which is essential for opioid 
activity (Ramamoorthy and Balasubramanian, 1992). In most cases, 
these peptides tend to share multiple opiate receptors to medi-
ate analgesic actions, even though they actually show distinctive 
preferences towards different opioid receptors. For example, the 
Abbreviations: APN, Aminopeptidase N; ME, Met-enkaphalin; LE, Leu-  enkaphalin; 
β-EP, β-Endorphin; Dyns, Dynorphins; EM, Endomorphin; KOR, κ-opioid recep-
tor; MOR, μ-opioid receptor; DOR, δ-opioid receptor; NLX, Naloxone; NEP, Neu-
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Figure 2 | The synthetic route of Bestatin.
marked inhibition of the degradation of these endogenous peptides 
attracts considerable attention due to its non-morphine-like addic-
tion. Hence, we have briefly summarized the development of this 
specific effect of peptidase inhibitors, exclusively Bestatin, on the 
enzymatic degradation of various natural analgesic substances in 
the human body in sequence to further estimate the possibility and 
potential role for Bestatin to serve in the nervous system.
Defining the inactivation pathway of opioid peptides allows us 
to understand the possibility that opioid catabolism inhibitors elicit 
typical opioid responses by increasing the amount of endopeptides 
in vivo. Therefore, the increased analgesic effects of endogenous lig-
ands by Bestatin may act on the opioid receptors, however, Bestatin 
and morphine have different mechanisms of action in the opioid 
system. It’s already known that chronic administration of morphine 
can induce tolerance and dependence, exhibiting a characteristic 
abstinence syndrome during the challenge of naloxone (NLX), 
an opioid antagonist, which can antagonize the antinociception 
of all the endogenous opioid ligands. Ozaki et al. (1994) firstly 
discovered that Bestatin could increase the ileal twitch inhibitory 
potency caused by ME as well as transient inhibition of twitch 
contraction after tetanic stimulation. These results suggested that 
Bestatin-sensitive aminopeptidase participated in the post-tetanic 
twitch inhibition. After a further study, the quantitatively different 
mechanisms of action in the opioid system between Bestatin and 
morphine were elucidated based on the fact that when challenged 
with NLX after a long exposure to the Bestatin and morphine 
respectively, the former didn’t induce any NLX-induced contraction 
which morphine did although they had similar effects on the post-
tetanic contraction, which suggested the possibility that Bestatin 
had a smaller dependence liability (Ozaki, 2002).
Variously natural opioid peptides could act as substrates of 
APN including ME, LE, Dyn1–6, and Dyn1–7, which were com-
monly catalyzed by the N-terminal hydrolysis of tyrosine (Griffin 
et al., 1992). It was also proved that ME hydrolyzing enzymes were 
involved in the degradation of not only ME but also β-EP and 
Dyns in the rat central nervous system (Kishioka et al., 1994). 
Though ME and β-EP acted on both supraspinal and spinal sites, 
Dyns acted only on the spinal site. So it can be concluded that 
Bestatin can affect several opioid peptides concurrently. Given the 
considerably complex substances in the human body relevant to 
the antinociception responses, in order to organize and summa-
rize more logically, we, followingly, deliberately state the analgesic 
effect of Bestatin in accordance with the list of each possibly related 
natural substance.
FunctIonal mechanIsms
enkaphalIns
An enkaphalin is a pentapeptide involved in regulating nociception 
in the body of which two forms are determined; they are Met-
enkaphalin (Tyr–Gly–Gly–Phe–Met) and Leu-enkaphalin (Tyr–
Gly–Gly–Phe–Leu). Both are products of the proenkaphalin gene 
and it has been identified that MOR, rather than DOR, appears to 
be involved in enkaphalin-induced analgesia (Chaillet et al., 1984) 
based on the observed highly affinity between various enkaphalin 
analogs for the central or peripheral MOR, not DOR.
The  inactivation  of  endogenous  enkaphalins  in  neutral 
endopeptidase (NEP) and APN has been proven by several experi-
ments (Dua et al., 1985; Leung et al., 1992; Miller et al., 1994; 
Kanai et al., 2002; Mosnaim Aron et al., 2004). Chaillet et al. www.frontiersin.org  June 2010  | Volume 4  | Article 50  |  3
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studied with the NEP-knockout mice. It’s already known that 
in the brain, pharmacological inhibition of NEP-activity caused 
analgesia resulting from enhanced extracellular enkaphalin con-
centration. However, Fischer et al. (2002) was surprised to find 
that the NEP-knockout mice suffered from bradykinin-induced 
hyperalgesia rather than enkaphalin-mediated analgesia, what’s 
more, Thiorphan, the NEP-inhibitor couldn’t reduce writhing in 
NEP-deficient mice. Fortunately, Bestatin did exert remarkably 
inhibitory effects in both the NEP-knockout mice and the wild-
type mice. This result further indicates the crucial role of APN 
in enkaphalin degradation.
On the other hand, the different metabolisms between ME and 
LE in the brain were investigated (Belyaev et al., 1990). Direct con-
firmation was obtained by determining changes in brain enkaphalin 
levels under the influence of Bestatin. It was surprised to note that 
Bestatin, which controlled the ME level in the midbrain, had no 
effect on the concentration of this peptide in the striatum, nor on 
the LE concentration in both parts of the brain studied. The selec-
tive action of Bestatin might indicate the regional differences of ME 
catabolism in the brain and also differences in the contribution of 
APN to the inactivation of ME and LE. A similar result was obtained 
by Jin et al. (1986) who reported that microinjection of Bestatin 
or Thiorphan into the nucleus accumbens of the rabbit produced 
a dose-dependent analgesic effect, which was totally reversed by 
NLX or by antibodies against ME administered to the same site, 
whereas antibodies against LE were not effective. Interestingly, 
Chaillet et al. (1983) and Mosnaim Aron et al. (2004) both suc-
cessfully observed the inhibitory effect of the co-administration of 
Bestatin and Thiorphan on the hydrolysis of [3H]LE by slices from 
rat striatum. Besides, they also proved that the two inhibitors used 
together could potently protect ME administered i.c.v. to potentiate 
its antinociceptive properties in mice. Also, Bestatin itself displayed 
antinociceptive properties. Thus, a Bestatin-sensitive enkaphalin 
aminopeptidase activity together with the enkaphalin dipeptidyl 
carboxypeptidase activity apparently was mainly responsible for the 
inactivation of both exogenous and endogenous enkaphalins. In 
addition to the above-mentioned regional difference of the LE effect 
in the brain, some experiments showed the distinctive administra-
tion techniques might also lead to distinguished responses of LE 
(Mizuma et al., 1997). In accordance with the experiment, no anal-
gesic effect was observed in the acetic acid writhing assay of mice 
after s.c. administration (for peripheral effect) of LE or cellobiose-
coupled LE (CcpLE) without peptidase inhibitors, whereas CcpLE 
as well as LE had analgesic activity by subcutaneous administration 
(s.c.) to mice pretreated with peptidase inhibitors, On the other 
hand, hot-plate assay (for central effect) did not indicate obvious 
analgesic effect after s.c. administration of CcpLE or EcpLE with 
pretreatment of peptidase inhibitors. Therefore, it was concluded 
that CcpLE was a peripherally active analgesic. Also, the prefer-
ence to different DORs was discovered in the mouse tail flick assay 
(Takemori and Portoghese, 1993). When LE or ME administered by 
i.c.v. together with the peptidase inhibitors, Bestatin and Thiorphan, 
the antinociceptive effects were significantly reversed by a selective 
DOR1 antagonist but not by a selective DOR2 antagonist. On the 
other hand, when given intrathecally (i.t.), the antinociceptive ED50 
values of both enkaphalins were significantly raised by the opposite 
receptor subtypes respectively.
(1983) found that not only the co-administration of Bestatin and 
Thiorphan, an enkaphalin dipeptidyl carboxypeptidase inhibitor, 
significantly protected [3H]ME-administered intracerebroven-
tricular (i.c.v.) to mice from hydrolysis, but also both the two 
drugs alone caused a strong reduction in the accumulation of 
ME hydrolysis products in the brain. Furthermore, the antino-
ciceptive activity of ME was additively potentiated by Bestatin 
and Thiorphan on either the hot-plate jump test or the phenyl-
benzoquinone writhing test, respectively. Also, the hydrolysis of 
[3H]LE by slices from rat striatum was observed to be inhibited 
in the presence of Bestatin and Thiorphan.
Carenzi et al. (1983) provided another evidence in vivo to the 
degradatative effects by APN and NEP through detecting the pain 
threshold changes of mice and rats in vivo when Bestatin and 
Thiorphan were administrated as selective peptidase inhibitors. 
The results indicated that both enzymes were responsible for the 
enkaphalins’ degradation. However, it was argued that only con-
comitant intracerebral treatment with both inhibitors led to an 
increase in the threshold of animal pain, besides, in the presence 
of exogenous peptides, the co-administration of two inhibitors 
in mice elicited a synergetic analgesic activity and this response 
could be seen only after acute trauma. Later, opioid peptides 
contributing to the stress-induced antinociception with inflamed 
peripheral tissues of rats were studied (Parsons and Herz, 1990). 
Cohen et al. (1983) further affirmed the critical role of APN for 
terminating the pharmacological actions of enkaphalins in intact 
guinea pig ileal preparations. From their experiments, Bestatin 
enhanced the efficacy of enkaphalin in the guinea pig ileum and 
ileal longitudinal muscle in a dose-dependent fashion. Bestatin 
also decreased the formation of [3H] tyrosine and increased [3H]
LE content. Later, Dickenson et al. (1987) stated that the enkapha-
lins may be degraded by at least three peptidases in the superficial 
dorsal horn of rabbit based on the study of three inhibitors of 
different peptidases by comparing the inhibitory effects medi-
ated by endogenous enkaphalins. These inhibitors were Bestatin, 
a non-specific aminopeptidase inhibitor, Thiorphan, an inhibi-
tor of NEP and Kelatorphan, a mixed inhibitor of several ami-
nopeptidases, all of which enhanced the antinociception under 
the experiment with Kelatorphan to be the most efficient one. By 
observing the intense change of the voltage, the analgesic effects of 
peptidase inhibitors were also approved (Piguet and North, 1993). 
According to the experiment, the hyperpolarization of dentate 
granule cells of rat hippocampal slices by ME was potentiated by 
Bestatin and Thiorphan and blocked by antagonists selective for 
both MOR and DOR. Suzuki et al. (1994, 1997) firstly tested the 
effects of peptidase inhibitors on physiological activities involv-
ing enkaphalins in the isolated spinal cord of the neonatal rat. 
Electrical stimulation of the saphenous nerve induced a slow ven-
tral root potential (VRP), which was depressed by enkaphalins and 
augmented by NLX, suggesting that an opioid peptide-operated 
inhibitory mechanism was involved in the slow VRP. This effect 
of ME was markedly potentiated by addition of the mixture of 
peptidase inhibitors owing to the inhibition of the degradation of 
ME. Bestatin alone could potentiate the depressant effect of ME, 
which was less effective compared with Thiorphan, but still sig-
nificantly inhibited the degradation by 65%. The important role 
of peptidases related to the hydrolysis of enkaphalins was recently Frontiers in Neuroscience  |  Neuropharmacology    June 2010  | Volume 4  | Article 50  |  4
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These observations indicated that the predominant inactivating 
mechanism for MEAP was through the action of APN. Recently, 
MEAP-induced antinociception in chronic treatment was assumed 
to be caused by interaction with all three opioid receptors (μ, δ, 
and κ) in rats and differently regulating their expression (Vats et al., 
2009). The analgesic activity could be potentiated by i.t. of Bestatin 
and Captoril owing to the accumulated recovery of MEAP.
β-endorphIne
β-Endorphin  is  released  into  blood  from  the  pituitary  gland 
and into the spinal cord and brain from hypothalamic neurons. 
Compared with other opioid peptides, β-EP is more resistant to 
the degrading-enzyme system thanks to its bigger molecular weight; 
nevertheless, once released into the blood it can’t enter the brain 
in large quantities because of the brain–blood barrier (BBB), so 
the physiological importance of the β-EP that can be measured 
in the blood is far from clear. β-EP has the highest affinity for 
the MOR1, a slightly lower affinity for MOR2 and DOR and low 
affinity for KOR. In common with ME, β-EP also plays an essential 
part in the antinociceptive system; actually, the β-EP may act as a 
releaser of ME. The effect of the intrathecal injection of Bestatin 
on the antinociception induced by β-EP administered i.c.v. was 
studied in male mice (Suh and Tseng, 1990b). In the experiment, 
antinociceptive effects were valued by the tail-flick and hot-plate 
tests which showed Bestatin could potentiate inhibition of the tail-
flick response induced by β-EP, but not antagonize inhibition of the 
hot-plate response. The results indicated that inhibition of the tail-
flick response, induced by β-EP administered i.c.v. was mediated 
by the opioid system rather than by noradrenergic or serotonergic 
systems in the spinal cord, whereas the hot-plate response might 
be involved in other responsive mechanisms.
Further, Suh and Tseng (1990a) hypothesized that the antinocic-
eption induced by β-EP was mediated by release of ME. The theory 
was based on the fact that β-EP injected into the fourth ventricle could 
increase immunoreactive ME in the spinal perfusate in urethane-
anesthetized rats; furthermore, Bestatin increased the amount of 
immunoreactive ME released by β-EP in a dose-  dependent manner. 
This was also identified by Takemori and Portoghese (1993), who 
found that β-EP-induced (i.c.v.) antinociception was antagonized 
by a selective DOR2 antagonist and potentiated by Bestatin, which 
seemed to have the same response with the enkaphalins admin-
istered i.t.. So it was assumed that the antinociception produced 
by i.c.v. administered β-EP was attributed to the release of ME in 
the spinal cord. However, some differences between the bioactive 
effects of β-EP and ME were also investigated based on the different 
reactions to the Bestatin. Compared to ME, β-EP also decreased 
the contractile responses to electrical field stimulation on airway 
smooth muscle (Horii et al., 1990) which was dose-dependent and 
reversed by NLX, however, was not augmented by the peptidase 
inhibitor, Bestatin, which is different from that of ME.
dynorphIns
Dynorphins are a class of opioid peptides that arise from the pre-
cursor protein prodynorphin. When prodynorphin is cleaved by 
proprotein convertase 2, multiple active peptides are released: Dyn 
A, Dyn B, and α/β-neoendorphin. Dyns exert their effects primarily 
through KOR, including KOR1 and KOR2. Besides, the peptides 
A large amount of work has been done to determine the precise 
active sites of APN to further understand the functional mecha-
nism of Bestatin. The specific effects of Bestatin on exogenous 
and  endogenous  ME-induced  antinociception  were  examined 
by a hot-plate method in mice (Matsuoka et al., 1988), which 
showed the elevation of pain threshold caused by an intracisternal 
administration of ME was enhanced by Bestatin and its analogs. 
Moreover, microinjection of Bestatin into the nucleus accumbens 
of rabbit resulted in a marked potentiation of the aftereffect of 
  electroacupuncture-produced analgesia, as well as the analgesia 
induced by a small dose of morphine, both effects of which were 
mediated, at least in part, by a ME-like immunoreactive substance 
(Jin et al., 1986). These results not only indicated that the inhibi-
tion of APN might augment the exogenous ME antinociception 
but also suggested that Bestatin and its analogs might cause the 
enhancement of the endogenous ME-mediated antinociception. 
Berg and Marks (1984) primarily illuminated the specific acting 
sites of an Bestatin-sensitive aminopeptidase purified to homoge-
neity from the cytosol of rat brain, which cleaved Dyns and selected 
proenkaphalins at the Tyr–Gly bond proved by the release of only 
Tyr and the des Tyr fragments. Later on, Anderson et al. (1998) also 
supported the theory employing different experimental systems, 
in which ME was proven to be most readily degraded by the oli-
gopeptidases contained in the venom of the Taiwan cobra, releasing 
a steady accumulation of Tyr, Gly–Gly and Phe–Met over time. The 
peptidase inhibitors, Bestatin and Thiorphan, were tested for their 
ability to inhibit the actions of the oligopeptidases. It was again 
verified that with ME as substrate, Bestatin inhibited the cleavage 
of the Tyr–Gly peptide bond depending on the observation of the 
reduced collection of Gly–Gly–Phe–Met, while there was no fall in 
the production of Tyr–Gly–Gly and Phe–Met and also an increase 
of Tyr–Gly–Gly. Meanwhile, Thiorphan was affirmed to accumulate 
the Gly–Phe peptide bond. Bestatin and Thiorphan also inhibited 
subsequent cleavage of the fragments Tyr–Gly–Gly and Gly–Gly–
Phe–Met, respectively. LE was also found readily hydrolyzed to free 
tyrosine and Gly–Gly–Phe–Leu in rat microglia compared with 
other glial cells (Lucius et al., 1995) and inhibition experiments and 
immunostaining revealed that APN on the surface of microglia was 
responsible for enkaphalin cleavage. Later, Mosnaim et al. (2000) 
affirmed the inhibitory role of Bestatin in humans of various char-
acters. They found that the [3H]LE degradation rate was pH and 
temperature dependent incubated in platelet-poor human plasma, 
which was independent of gender, age, or even the physical condi-
tion based on the observation that LE degradation was all rapid and 
complete in any case. More importantly, they pointed out that LE 
degradation was strongly and similarly inhibited by Bestatin with 
a lesser extent of various l-tyrosine-containing Leu fragments.
The  antinociceptive  effects  of  several  enkaphalin  analogues 
were also studied, among them, the heptapeptide, ME–Arg6–Phe7 
(MEAP) was the exemplary one. As a precursor of ME, MEAP was 
indicated as an independent neuromodulator exhibiting the anal-
gesic effect in vivo. Tang et al. (1983) claimed that APN might be 
important in the degradation of MEAP in vivo by using a prepara-
tion for the perfusion of the subarachnoidal spaces of the spinal cord 
of rats. Reggiani et al. (1984) reported that Bestatin could drastically 
potentiate the analgesic effect induced by the intracerebral injection 
of MEAP in cannulated rats, but Thiorphan was totally ineffective. www.frontiersin.org  June 2010  | Volume 4  | Article 50  |  5
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Like the previously mentioned two types of peptides, Dyns 
similarly depressed the cholinergic twitch contractions of circu-
lar muscle strips from the guinea pig proximal colon induced by 
single pulse electrical field stimulation, which was abolished by 
atropine (Giuliani et al., 1996). This result totally contradicted the 
point that acetylcholine-induced contractions were not affected by 
Dyns as demonstrated before (Horii et al., 1990). Dyn A exhibited 
concentration-dependent inhibition of twitches, which could be 
enhanced by Bestatin and other peptidase inhibitors. Therefore, 
cholinergic twitches were considered to be modulated by multiple 
opioid receptors, among the KORs, activated by Dyn A1–13, medi-
ating a powerful inhibition of acetylcholine release.
kyotorphIn
Kyotorphin, an endogenous ME-releasing antinociceptive dipep-
tide (l-Tyr–l-Arg), primarily obtained from the bovine rain, was 
formed by KTP synthetase from its constituent amino acids: l-Tyr 
and l-Arg, in an ATP-Mg2+-dependent manner. KTP produces 
analgesic effects possibly through ME release, by activating opioid 
receptors, especially the DOR (Takagi et al., 1979; Kawabata et al., 
1996a). Subsequently, Akasaki and Tsuji (1991) and Akasaki et al. 
(1991) ensured the degradating role of Bestatin-sensitive ami-
nopeptidase, which could also catalyze the hydrolysis of LE and 
ME. Consequently, KTP was degraded by the aminopeptidase with 
a compatible Km value to those of LE and ME, and this conclu-
sion was further identified using immunological analysis. Later 
on, a newly synaptic membrane-bound peptidase was supposed 
as a novel KTP-degrading enzyme which was inhibited by Bestatin 
exclusively in rat brain synaptosomes (Orawski and Simmons, 
1992). Bestatin could also degrade other dipeptides including Phe–
Arg, a synaptic membrane-generated metabolite of bradykinin. The 
deactivation of KTP in rats was studied by employing an amino acid 
analyzer, showing that Bestatin strongly inhibited the hydrolysis of 
KTP (Matsubayashi et al., 1984; Ueda et al., 1985a,b). According 
to the experiment, a dose of 50 μg of Bestatin administered intra-
cisternally potentiated the analgesic activity of KTP by 4.8 times 
or so, and this effect was abolished by pretreatment with NLX. 
These facts suggested that the potentiation of analgesia by Bestatin 
might be due to the protection against the degradation of KTP and 
the release of enkaphalin by a membrane-bound aminopeptidase. 
Moreover, Satoh et al. (1985) claimed that the protection of Bestatin 
differed among regional areas based on the observation that co- 
administration of Bestatin with KTP enhanced the analgesic effect 
in the periaqueductal gray and lumbosacral subarachnoid space but 
not in the nucleus reticularis paragigantocellularis.
Later on, KTP synthetase was reported to also exist in the adrenal 
gland, in addition to the central nervous system (Kawabata et al., 
1996b), therefore, the peripheral contribution of KTP in pain regu-
lation was studied (Inoue et al., 1997). Bradykinin given into the 
plantar region of the mouse hind-limb produced a flexor response, 
and KTP produced a dose-dependent reduction of the BK-induced 
nociceptive responses, which was not reversed by NLX, taking it 
into consideration that KTP-induced analgesia by central admin-
istration was completely blocked by NLX; therefore, the findings 
indicated that KTP produced analgesia through direct inhibition 
on Bradykinin responses without opioid mechanisms in peripheral 
tissues. It was also noteworthy to mention that the prerequisite of 
also have some affinities for MOR and DOR, meanwhile, different 
Dyns show different selectivities and potencies towards receptors. 
Calculating on a molar basis, Dyns can be 6–10 times more potent 
than morphine and 65–100 times more potent than morphiceptin, 
which was partially reversed by NLX (Han and Xie, 1982). Berg 
and Marks (1984) discovered an aminopeptidase, consisting of a 
single polypeptide chain when purified to homogeneity from the 
cytosol of rat brain, that cleaved Dyns having 5–17 residues and 
selected proenkaphalins at the Tyr–Gly bond to release Tyr and the 
desTyr fragments, which was inhibited by Bestatin in the micro-
molar range. Nakazawa et al. (1989) found that intracerebrally 
administered Dyn-B produced both an analgesia through opioid 
receptors and a motor dysfunction through non-opioid receptors 
in mice with the same dosage. More notably, Bestatin markedly 
potentiated the antinociceptive response induced by Dyn-B but not 
the motor dysfunction, and the potentiation could be antagonized 
by NLX. Another experimental result implied that some special 
conditions might be necessary for Bestatin to inhibit Dyns’ deg-
radation. [3H]Dyn A 1–8 and [3H]Dyn A 1–9 with suspensions 
of guinea pig brain membrane could be both degraded at 25 and 
at 0°C (Gillan et al., 1985). Bestatin reduced degradation at 0°C 
and exhibited a similar degree of protection at 25°C. Additionally, 
Bestatin exerted less effect when the Dyns were bound with opioid 
receptor. Muller et al. (1995) illustrated the metabolism of Dyn 
A1–13 in human blood and plasma through the combination of 
enzyme inhibition experiments and non-compartmental kinetic 
analysis. They claimed that Dyn A1–13 was mainly metabolized 
by aminopeptidases and by carboxypeptidases, Bestatin-sensitive 
endopeptidases metabolized 30% of the subsequent product, Dyn 
A2–12. Based on the inhibitory roles of two types of neuropepti-
dases: NEP and APN, the combination of Bestatin plus Thiorphan 
could produce an increase in the level of both enkaphalins and 
Dyns family peptides. Cannabinoids elicited antinociception both 
at spinal and supraspinal levels, which can be readily potentiated 
by simultaneous activation of the opioid system and therefore, was 
therapeutically promising. ∆9-tetrahydrocannabinol (∆9-THC), the 
most psychoactive natural cannabinoid, elicited antinociception 
in rodents through the central CB1 cannabinoid receptor subtype 
(Reche et al., 1998). In addition, ∆9-THC stimulated the release of 
Dyn-related peptides leading to κ-opioid spinal antinociception. 
Based on the existing knowledge that morphine was able to enhance 
cannabinoid antinociception, Bestatin was studied to identify its 
possible effect coupling with ∆9-THC, and the result showed its 
enhancement of the antinociceptive response of ∆9-THC, which 
was blocked by the CB1 cannabinoid receptor antagonist, as well 
as by NLX. This offered some encouragement to develop a new 
type of analgesic drug that might simultaneously activate both 
cannabinoid and opioid receptors.
Conversely, other studies have shown Dyn A is an endogenous 
opioid peptide that produces non-opioid receptor-mediated neural 
excitation identifying a role for Dyn and KOR stimulation in neuro-
pathic pain (Lai et al., 2006; Mei et al., 2007). Furthermore, this group 
also reported that the Dyn-KOR system mediated astrocyte prolifera-
tion through the activation of p38 MAPK that was required for the 
effects of neuropathic pain on analgesic responses. Taken together, 
these results suggest that Dyn can elicit multiple effects on both KOR 
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also contains the related neuropeptide neuromedin U (NM U), 
NM U is a highly conserved neuropeptide present in many spe-
cies, existing as multiple isoforms; in humans, it is a 25 amino acid 
peptide. Both NT and its congener, NM, administrated i.c.v. in mice 
induce antinociceptive activity. Structure–activity studies reveal a 
close correlation between the analgesic potency of NT analogs and 
their affinity for the NT receptor 2 (NTR2) and discloses potent 
and selective agonists of this receptor, which confirms the fact that 
NTR2 mediates NT-induced analgesia.
The analgesic effects of both NT and NM were tested by the 
writhing and the tail-flick test (Coquerel et al., 1988). Compared 
to NT, the effect of NM was poorer. Bestatin alone promoted anti-
nociceptive effects of NM with subthreshold dose in the tail-flick 
test though maximal antinociception was obtained by combining 
other inhibitors. More notably, NLX did not reduce the antino-
ciceptive effect of either NT or NM indicating that NT and NM 
elicited analgesia in mice through an opiate-independent mecha-
nism. Despite its peculiarity, Bestatin-sensitive aminopeptidase 
can degrade NM and has comparatively little effect on the NT. 
Fernandez and Alba (1996) further affirmed the crucial role of 
endogenous  peptidases  implicated  in  the  inactivation  of  NT 
and NM in the prefrontal cortex by observing the inhibition of 
intracranial self-stimulation (ICSS) produced by injections of 
NT and NM into the medial prefrontal cortex of the rat. They 
studied the inhibitory change on ICSS after the administration of 
Bestatin and Thiorphan, two specific inhibitors of the peptidases 
that inactivate NM and NT, respectively, obtaining the result that 
microinjections of Bestatin and Thiorphan potentiated the inhi-
bition of ICSS produced by the intracortical administration of 
NM and NT, correspondingly. The potentiation affected both the 
amplitude and the duration of the inhibition of ICSS produced 
by the neuropeptides.
other natural substances
In addition to the above-mentioned natural peptides which are 
closely related with the analgesic activity of Bestatin, a large number 
of other relevant substances have been discovered.
Tuftsin (Thr–Lys–Pro–Arg)
Produced by enzymatic cleavage of the Fc-domain of the immu-
noglobulin  G  (Herman  et  al.,  1981,  1983;  Ramamoorthy  and 
Balasubramanian, 1992) and by acting as a naturally occurring 
immunopotentiating factor, also had marked analgesic activity. A 
cytosolic monkey brain aminopeptidase was responsible for cleav-
ing tuftsin, which was inhibited by Bestatin.
The proenkephalin A-processing product peptide E (PE)
An opioid peptide originally isolated from the bovine adrenal 
medulla, was known to possess very low analgesic potency when 
injected by i.c.v. in mice alone (Westphal et al., 1985). However, 
the co-injection with Bestatin showed that PE-induced analge-
sia was increased remarkably. Inconsistently, Condamine et al. 
(1999) later rejected the potential PE-induced analgesia with the 
evidence that concomitant administration of PE with Bestatin 
did not produce analgesic responses. Therefore, further research 
on the structural and pharmacological characteristics of PE is 
urgently required.
the effective antinociception of KTP was the presence of Bestatin 
given prior to the BK injection, When KTP was administered alone, 
the ED50 was disastrously higher and there was a complete recovery 
later. This further argues the significant protection of KTP from 
aminopeptidase by Bestatin.
endomorphIns
Endomorphins, isolated from bovine and human brain (Zadina et al., 
1997), comprise two endogenous opioid peptides:   endomorphin-1 
(EM-1)  (Tyr–Pro–Trp–Phe–NH2)  and  endomorphin-2  (EM-2) 
(Tyr–Pro–Phe–Phe–NH2), both of which are tetrapeptides with 
the highest affinity and specificity for the MOR to exert efficient 
antinociception (Zadina et al., 1999), which can be blocked by 
NLX. The physiological action of EMs as neurotransmitters or 
neuromodulators in the central nervous system is closely related 
to the degradation of EMs by peptidases. APN, due to the peptide 
bond type of its degradation, was assumed to play a crucial role 
in EM-degradation to tripeptides (Dua et al., 1985; Harbeck and 
Mentlein, 1991). Nevertheless, compared with the active sites of 
Bestatin on either enkaphalins or Dyns, some distinctive inhibitory 
mechanism was found as to that of EMs. Sakurada et al. (2003) and 
Sakurada (2004) reported that NEP and APN would be mainly 
responsible for the degradation of EM-2 at the synapse. In accord-
ance with their experiment, NEP, as the first enzyme, cleaved EM-2 
at the Pro2–Phe3 bond to generate Tyr–Pro and Phe–Phe–NH2, 
from which free phenylalanine and Phe–NH2 were produced by 
APN. This was proved by the fact that Bestatin could markedly 
enhance the generation of Phe–Phe–NH2, whereas free Phe and 
Phe–NH2 were decreased. These results might imply the involve-
ment of APN in secondary cleavage of the initially formed cleav-
age products by the action of NEP; therefore, Bestatin might have 
relatively less effect on the degradation of EM-2 at supraspinal level. 
However, it was also noteworthy that Bestatin produced a large 
amount of Pro–Phe–Phe–NH2 whose peak was not detected in the 
absence of Bestatin, indicating the additional protection of Pro–Phe 
bond. In the behavioral studies, i.c.v. or i.t. administered EMs sig-
nificantly increased nociceptive thresholds, which was blocked by 
NLX, implying that EMs might play a physiological role in modu-
lating pain at the spinal and supraspinal levels (Fichna et al., 2007). 
Further research implied that the antinociception induced by EM-2 
might be mediated by the release of Dyn A1–17 and ME, which 
subsequently acted on KORs and DORs to produce antinociception 
(Tseng et al., 2000; Sakurada et al., 2001).
The peripheral effect of EM-1 was primarily studied by Li et al. 
(2001). In the experiment, EM-1 raised the pain threshold dose-
dependently in tail stimulation-vocalization test in rats and inhibited 
the acetic acid writhing responses of mice, although the analgesic 
effect induced by peripheral intraperitoneal (i.p.) administration 
was obviously slower and weaker than that of the central (i.c.v. and 
i.t.) administration. However, both analgesic effects of EM-1 were 
reversed by NLX, which may predict the possible inhibitory effects 
of Bestatin, although no direct research has been done up to now.
neurotensIon and neuromedIn u
Neurotension (NT) is a 13 amino acid neuropeptide (Glu–Leu–
Tyr–Glu–Asn–Lys–Pro–Arg–Arg–Pro–Tyr–Ile–Leu–OH), which is 
synthesized as part of a 169–170 amino acid precursor protein that www.frontiersin.org  June 2010  | Volume 4  | Article 50  |  7
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Kelatorphan, leading to NLX-reversible analgesic responses, that 
were slightly better than those produced by Bestatin and were also 
more efficient in potentiating the analgesia induced by a subanal-
gesic dose of ME (Fournie-Zaluski et al., 1985). More analogues of 
Bestatin were found to inhibit the hydrolysis of β-EP in different 
assay systems (Shang et al., 2008).
Co-administration
Another more advisable method to ensure the best use of Bestatin 
is the co-administration of the other drugs in a synchronic man-
ner, which often involves several peptidases. Typical combinations 
included Bestatin or amastatin to inhibit APN, Thiorphan, or 
Phosphoramidon to inhibit NEP, and Captopril to inhibit angi-
otensin-convertion enzyme are effective in preventing the metabolic 
breakdown of a variety of opioid peptides (Hiranuma et al., 1998). 
The antinociceptive effect of i.t. administered Phosphoramidon 
and Bestatin was observed against the   capsaicin-induced paw 
licking and biting response in mice (Tan-No et al., 1998), which 
was significantly antagonized by naltrindole, a selective DOR 
antagonist. Thus, Phosphoramidon coupling with Bestatin may 
block the degradation of enkaphalin. Cathinone-induced anal-
gesia depended upon stimulation of α-adrenoceptors, which was 
counteracted by phenoxybenzamine. However, Bestatin strongly 
potentiated  Cathinone-induced  analgesia  and  this  effect  was 
sensitive to both NLX and Phenoxybenzamine blockade (Della 
Bella et al., 1985). Romero et al. (2009) reported that Bestatin 
remarkably potentiated the peripheral antinociceptive effect of 
Xylazine, an α2-adrenoceptor agonist by activating opioid recep-
tors via endogenous opioid release. Also, Bestatin was found to 
enhance the analgesic effect of Celecoxib, a selective inhibitor of 
cyclooxygenase-2 in a model of peripherally induced inflamma-
tory pain in rats (Rezende et al., 2009).
Dual inhibitors
Another powerful strategy as to develop ‘physiological’ analgesics 
devoid of the side effects of morphine is the application of the dual 
inhibitors, which can be metabolized once inside the brain to form 
two selective enzyme inhibitors and blocking both types of the 
zinc-metallopeptidase and enkaphalinase enzymes, resulting in the 
increase concentration of enkaphalins (Roques and Noble, 1995; 
Le Guen et al., 2003; Noble and Roques, 2007). These findings may 
constitute promising data for future development of a new class of 
analgesics that could be of major interest in severe and persistent 
pain syndromes.
neuropeptIdes
The non-addictive morphine-like activity indicates that neu-
ropeptides  could  potentially  replace  the  morphine  in  pain 
management (Otero et al., 1993). However, as mentioned at the 
beginning, the therapeutic applications of these peptides for vari-
ous disease conditions are restricted by their susceptibility to 
rapid degradation in biological systems. Furthermore, the BBB 
generally prevents the entry of peptides into the brain either by 
enzyme degradation or by specific properties of the BBB. Up 
to now, several tactics have been taken to prevent the transient 
degradation as well as the transportation barrier concerned with 
natural peptides.
I-Menthol
An effective counterirritant has been widely used in the treatment 
of mild pains and itches by topical application. Taniguchi et al. 
(1994) found that I-Menthol-induced analgesia in the hot-plate test 
and hind paw pressure test of rats was both significantly potenti-
ated by Bestatin and blocked by NLX. However, I-Menthol did 
not inhibit either carrageenin-induced paw edema of rats or the 
synthesis of prostaglandin E2 in vitro. All these observations sug-
gested that I-menthol produced antinociceptive effects by activating 
the endogenous opioid system.
l-Arginine produced central antinociception by acting as a precursor 
of KTP
l-Ornithine, a metabolite of l-arginine, was assumed to produce 
l-arginine-like antinociception via KTP receptors. Kawabata et al. 
(1996a) identified this hypothesis depending on the evidence both 
l-Ornithine and l-arginine, when given by i.c.v. to mouse, elicited 
antinociception on the carrageenin-induced hyperalgesia even in 
intact mice, the effects being potentiated by Bestatin and abol-
ished by NLX.
Substance P1–7
As one of the major metabolites of Substance P, administered 
by  i.t.  could  increase  tail-flick  latency  in  a  dose-dependent 
manner in the mouse tail-flick test. As endopeptidase played a 
major role in Substance P degradation in the mouse spinal cord, 
Bestatin potentiated the antinociception having only a mild effect 
(Sakurada et al., 2004).
More interestingly, Bestatin was discovered to be a powerful 
inducer of wound-response genes in tomato through specifically 
activating jasmonic acid signaling in plants, which can enhance 
the  plant  resistant  system  to  various  exotic  nociceptive  pain 
(Zheng et al., 2006).
problems and strategIes
After a brief summary of the analgesic activity of Bestatin and 
its concerned biological substances, it can be safely concluded 
that the co-administration of Bestatin and the various peptides 
will offer us a newly promising strategy for the development of a 
creative class of analgesic. It is, however, quite necessary to point 
out that there are numerous drawbacks concerned about both of 
the two aspects.
bestatIn
The first issue is Bestatin’s marked toxicity and non-specificity 
(Giros  et  al.,  1986;  Bauvois  and  Dauzonne,  2006)  by  inhibit-
ing  other  membrane-bound  metalloproteases  such  as  Leucyl-
aminopeptidase,  aminopeptidase  B  and  aminopeptidase  W  or 
matrix metalloproteinases, suggesting that some of the observed 
chemotherapeutic actions of Bestatin may be due to inhibition of 
other cell surface peptidases. Together, these observations empha-
size the need for more specific and targeted APN inhibitors.
Bestatin analogs
In order to counteract the negative problems with Bestatin, some 
analogs of Bestatin have been designed, synthesized and evalu-
ated  by  i.c.v.  injection  in  mice,  several  compounds,  especially Frontiers in Neuroscience  |  Neuropharmacology    June 2010  | Volume 4  | Article 50  |  8
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